|Day Low/High||264.25 / 267.65|
|52 Wk Low/High||208.07 / 287.94|
Procter & Gamble proxy fight is an intriguing distraction.
Changes in economy have shored up weak areas.
Here comes some volatility in the markets.
The Senate just unveiled more details about its health care reform bill.
We forget that a big hedge fund or mutual fund switching out of tech winners into everything else can roil the market.
From price momentum to signs of irrational exuberance, several things have me worried.
These three stocks are showing short-term gain catalysts and longer-term growth potential.
It's a wonder to me how split this market really is.
Stocks closed lower after digesting mixed first quarter earnings data.
So far, the biggest in whatever sectors have benefited the most from his presidency.
Repatriation of profits would bring in money and tax revenue.
British Prime Minister Theresa May is calling for a 'snap' or general election on June 8th.
Goldman Sachs and Bank of America release earnings on Tuesday.
Their overseas business has been carrying them.
Neither the Affordable Care Act nor the American Health Care Act did enough to address rising health-care costs.
Take a closer look at four stocks professional investors are loving in 2017.
This reversal has been incredible to watch.
Healthcare stocks had a heckuva four-year period of over-performance that ended in the summer of 2015. Since then the Health Care Select Sector SPDR ETF (40% pharma and 15% biotech) has had a series of trading-range moves as sector prices lagged. La...
There are too many zero-sum games being portrayed as win-wins.
Wall Street holds mostly lower in a quieter end to a record-breaking week in which stocks scored their best winning streak in a quarter century.
Kaleo's EpiPen compeitor the Auvi-Q was released today.
Here's why fund managers have been betting on these blue-chip stocks in a big way during the most recent quarter.
If you look at the earnings reports, not the articles, you'd have found reasons to buy.